Cargando…

Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches

Type 2 diabetes mellitus (T2DM) is a progressive disease with a growing prevalence, associated with an increased risk of complications. The introduction of new classes of antidiabetic drugs into clinical practice has dramatically changed the landscape of diabetes therapy. However, despite the progre...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasdeki, Dimitra, Koufakis, Theocharis, Tsamos, Georgios, Busetto, Luca, Zebekakis, Pantelis, Kotsa, Kalliopi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695991/
https://www.ncbi.nlm.nih.gov/pubmed/36432488
http://dx.doi.org/10.3390/nu14224801
_version_ 1784838203754151936
author Vasdeki, Dimitra
Koufakis, Theocharis
Tsamos, Georgios
Busetto, Luca
Zebekakis, Pantelis
Kotsa, Kalliopi
author_facet Vasdeki, Dimitra
Koufakis, Theocharis
Tsamos, Georgios
Busetto, Luca
Zebekakis, Pantelis
Kotsa, Kalliopi
author_sort Vasdeki, Dimitra
collection PubMed
description Type 2 diabetes mellitus (T2DM) is a progressive disease with a growing prevalence, associated with an increased risk of complications. The introduction of new classes of antidiabetic drugs into clinical practice has dramatically changed the landscape of diabetes therapy. However, despite the progress made in the pharmacotherapy of T2DM, mitigating the burden of the disease on individuals, societies and health care systems remains a challenge. Remission has recently emerged as a therapeutic target in T2DM, achievable through a wide range of interventions. Recent studies have shown that extensive lifestyle changes, such as weight reduction, bariatric surgery, and intensive glucose lowering therapy, can prompt the remission of diabetes, but some unanswered questions remain regarding its long-term effects on diabetic complications. Metabolic surgery and novel classes of glucose-lowering medications are currently the most effective interventions to induce weight loss and by extension remission in patients with diabetes; however, the ideal strategy to achieve the long-term maintenance of remission remains doubtful. In this narrative review, we discuss the available therapeutic approaches to target the remission of diabetes through personalized multimodal care, based on the latest evidence.
format Online
Article
Text
id pubmed-9695991
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96959912022-11-26 Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches Vasdeki, Dimitra Koufakis, Theocharis Tsamos, Georgios Busetto, Luca Zebekakis, Pantelis Kotsa, Kalliopi Nutrients Review Type 2 diabetes mellitus (T2DM) is a progressive disease with a growing prevalence, associated with an increased risk of complications. The introduction of new classes of antidiabetic drugs into clinical practice has dramatically changed the landscape of diabetes therapy. However, despite the progress made in the pharmacotherapy of T2DM, mitigating the burden of the disease on individuals, societies and health care systems remains a challenge. Remission has recently emerged as a therapeutic target in T2DM, achievable through a wide range of interventions. Recent studies have shown that extensive lifestyle changes, such as weight reduction, bariatric surgery, and intensive glucose lowering therapy, can prompt the remission of diabetes, but some unanswered questions remain regarding its long-term effects on diabetic complications. Metabolic surgery and novel classes of glucose-lowering medications are currently the most effective interventions to induce weight loss and by extension remission in patients with diabetes; however, the ideal strategy to achieve the long-term maintenance of remission remains doubtful. In this narrative review, we discuss the available therapeutic approaches to target the remission of diabetes through personalized multimodal care, based on the latest evidence. MDPI 2022-11-13 /pmc/articles/PMC9695991/ /pubmed/36432488 http://dx.doi.org/10.3390/nu14224801 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Vasdeki, Dimitra
Koufakis, Theocharis
Tsamos, Georgios
Busetto, Luca
Zebekakis, Pantelis
Kotsa, Kalliopi
Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
title Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
title_full Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
title_fullStr Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
title_full_unstemmed Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
title_short Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
title_sort remission as an emerging therapeutic target in type 2 diabetes in the era of new glucose-lowering agents: benefits, challenges, and treatment approaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695991/
https://www.ncbi.nlm.nih.gov/pubmed/36432488
http://dx.doi.org/10.3390/nu14224801
work_keys_str_mv AT vasdekidimitra remissionasanemergingtherapeutictargetintype2diabetesintheeraofnewglucoseloweringagentsbenefitschallengesandtreatmentapproaches
AT koufakistheocharis remissionasanemergingtherapeutictargetintype2diabetesintheeraofnewglucoseloweringagentsbenefitschallengesandtreatmentapproaches
AT tsamosgeorgios remissionasanemergingtherapeutictargetintype2diabetesintheeraofnewglucoseloweringagentsbenefitschallengesandtreatmentapproaches
AT busettoluca remissionasanemergingtherapeutictargetintype2diabetesintheeraofnewglucoseloweringagentsbenefitschallengesandtreatmentapproaches
AT zebekakispantelis remissionasanemergingtherapeutictargetintype2diabetesintheeraofnewglucoseloweringagentsbenefitschallengesandtreatmentapproaches
AT kotsakalliopi remissionasanemergingtherapeutictargetintype2diabetesintheeraofnewglucoseloweringagentsbenefitschallengesandtreatmentapproaches